|
“We are pleased to present
“Tom Equels is a deserving recipient of BioFlorida’s ‘Entrepreneur of the Year’ award. Tom left a highly successful legal practice in 2016 to assume the leadership role at AIM. In less than four years he has positioned Ampligen — its principal lead drug — in a large number of promising clinical trials, as well as established financial stability at AIM. Tom’s progress in proving the enormous potential of Ampligen has been remarkable,” said
AIM’s flagship products are Ampligen (rintatolimod) and Alferon N Injection. Ampligen is being evaluated as a potential therapeutic for COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), for multiple types of cancers and as a viral vaccine adjuvant. Alferon is a natural interferon that is approved in the
In a potential breakthrough, Ampligen has demonstrated the potential for standalone efficacy in the clinical setting in pancreatic cancer. In this regard, AIM recently announced receipt of statistically significant positive pancreatic cancer survival results from a multi-year Early Access Program conducted at
Safety and efficacy of Ampligen is also being studied in several immuno-oncology clinical trials at highly respected NCI-Designated Cancer Centers; two of which are in combination with the checkpoint blockade drug pembrolizumab. The
AIM recently signed a clinical trial agreement with
About BioFlorida
BioFlorida is the voice of Florida’s life science industry, representing 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors that collectively employ 87,000 Floridians. [Source: The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life (TEConomy/BIO, 2016)] BioFlorida’s member driven initiatives provide a strong business climate for the advancement of innovative products and technology that improve lives and promote economic benefits to the state. Link to their website
About
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act (PSLRA) of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 or COVID-19-induced CFS-like cases or immuno-oncology in humans and no assurance can be given that it will be the case. Additionally, no assurance can be given as to whether the current or planned trials will be initiated and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, a change in priorities at the institutions sponsoring other trials or will require additional funding. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful, or yield any useful data or require additional funding. Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Human clinical trials will be necessary to prove whether or not Ampligen will be efficacious in humans. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced.
BioFlorida Contact:
Courtney Cox, PR Counsel
(850) 559-0708
CourtneyC@TheMooreAgency.com
AIM Contact:
Phone: 212-671-1021
Email: aim@crescendo-ir.com
Phone: 800-778-4042
Email: IR@aimimmuno.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b36f596a-c136-491f-b1bc-c45c02f778d9
Source:
2020 GlobeNewswire, Inc., source